InCarda Therapeutics Raises $30 Million Through First Close of Series C Equity Financing
October 21, 2020 08:05 ET
|
InCarda Therapeutics, Inc.
Proceeds to Support Ongoing Clinical Development of InRhythm™, A First-of-its-Kind Inhaled Antiarrhythmic for Treatment of Paroxysmal Atrial Fibrillation (PAF) Positive Phase 2 Data Scheduled for...
Global Surgical Sealants and Adhesives Market Is Expected to Reach USD 4.34 billion by 2027 : Fior Markets
September 17, 2020 04:00 ET
|
Fior Markets
Newark, NJ, Sept. 17, 2020 (GLOBE NEWSWIRE) -- As per the report published by Fior Markets, the global surgical sealants and adhesives market is expected to grow from USD 2.08 billion in 2019 and to...
Liquidia Announces Notice of Allowance for U.S. Patent Application Covering Methods of Treating Pulmonary Hypertension with Dry Powder Treprostinil
August 28, 2020 07:15 ET
|
Liquidia Technologies, Inc.
RESEARCH TRIANGLE PARK, N.C., Aug. 28, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and...
Liquidia Reports First Quarter 2020 Financial Results and Provides Corporate Update
May 11, 2020 16:01 ET
|
Liquidia Technologies, Inc.
Received FDA Acceptance of LIQ861 NDA for ReviewReported Final Safety and Tolerability Results for LIQ861 Inspire TrialManagement to Host Webcast and Conference Call Today at 4:30p.m. ET ...
Surgical quality improvement initiative reduces postoperative pulmonary complications over decade
April 30, 2020 13:12 ET
|
The Joint Commission
Study in May 2020 issue of The Joint Commission Journal on Quality and Patient Safety OAKBROOK TERRACE, Ill., April 30, 2020 (GLOBE NEWSWIRE) -- A new study in the May issue of The Joint...
Monaghan Medical Corporation Announces FDA Clearance for New Respiratory Treatment Option
January 07, 2020 08:40 ET
|
Monaghan Medical Corporation
PLATTSBURGH, N.Y., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Monaghan Medical Corporation (MMC) today announced the newly approved combination for two of its groundbreaking products—the Aerobika®...
InCarda Therapeutics Appoints Daniel G. Welch as Executive Chairman of Board of Directors
April 03, 2019 08:00 ET
|
InCarda Therapeutics, Inc.
SAN FRANCISCO, April 03, 2019 (GLOBE NEWSWIRE) -- InCarda Therapeutics, Inc. (“InCarda”), a privately-held biopharmaceutical company developing first-of-their-kind inhaled therapies for...
New Patent Issuances Strengthen InCarda Therapeutics’ Intellectual Property Portfolio Covering Novel Inhaled Cardiovascular Therapies
February 07, 2019 08:05 ET
|
InCarda Therapeutics, Inc.
U.S. Patent Broadly Expands Coverage for Inhaled Treatment of Cardiovascular Disease to Include all Class I – IV Antiarrhythmic Drugs Additional U.S. Patent Provides Coverage for Combination of...
BioNebicine Corp. Commences Tests of Nebulizer Device
September 04, 2018 13:48 ET
|
BioNebicine Corp.
St. Petersburg, FL, Sept. 04, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioNebicine Corp. (“BioNebicine” or the “Company”) a privately held biotech company, is pleased to announce that it has...
Significant reductions in costly pulmonary complications with use of drug-free device
June 20, 2018 07:45 ET
|
Monaghan Medical Corporation
PLATTSBURGH, N.Y., June 20, 2018 (GLOBE NEWSWIRE) -- Post-operative pulmonary complications (PPCs) are a major burden to the healthcare system. A new real-world study published in Pulmonary...